Lynozyfic-Linvoseltamab-Gcpt
Lynozyfic is a monotherapy for adults with relapsed and refractory multiple myeloma after ≥3 prior therapies. This bispecific T-cell engager bridges CD3 on T-cells with BCMA protein on myeloma cells to activate cancer-cell killing. FDA and EMA approved for heavily pretreated patients who have exhausted standard treatment options.
Andembry-Garadacimab-Gxii
Andembry is a preventive therapy for hereditary angioedema (HAE) in adults and adolescents 12+ years. This selective Factor XIIa inhibitor targets the top of the inflammatory cascade with once-monthly dosing. FDA-approved in June 2025, offering the first monthly prophylactic HAE treatment targeting Factor XIIa.
Enflonsia-Clesrovimab-Cfor
ENFLONSIA is a long-acting, preventive monoclonal antibody developed to protect infants against a broad range of respiratory syncytial virus (RSV) disease severity. This includes severe cases that may lead to hospitalization. It is the first and only RSV preventive option that offers a weight-independent, single-dose administration, simplifying protection across all infants regardless of size or […]
Emrelis-Telisotuzumab Vedotin-Tllv
Emrelis is an antibody‑drug conjugate for adults with locally advanced or metastatic non-squamous non-small cell lung cancer overexpressing c‑Met after prior therapy. It delivers targeted chemotherapy directly to cancer cells to inhibit tumor progression.
Penpulimab-Kcqx-Penpulimab-Kcqx
Penpulimab‑Kcqx is an intravenous PD‑1 inhibitor used with chemotherapy to treat recurrent or metastatic non-keratinizing nasopharyngeal carcinoma. It boosts immune response to help control tumor growth in patients who have progressed after prior therapies.
Imaavy-Nipocalimab-Aahu
Imaavy is an IV antibody for adults and teens aged 12 and older with generalized myasthenia gravis who test positive for AChR or MuSK antibodies. It targets and blocks the FcRn receptor to reduce harmful autoantibodies and improve muscle strength.
